PBH

Prestige Consumer
NYSE

Real-time Quotes | Nasdaq Last Sale

34.30
+0.14
+0.41%
Opening 14:11 10/22 EDT
OPEN
34.12
PREV CLOSE
34.16
HIGH
34.39
LOW
33.83
VOLUME
173.77K
TURNOVER
--
52 WEEK HIGH
46.12
52 WEEK LOW
27.40
MARKET CAP
1.72B
P/E (TTM)
11.47
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Hedge Funds Are Warming Up To Prestige Consumer Healthcare Inc. (PBH)
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of June 30th, when the S&P 500 Index was trading around the […]
Insider Monkey · 10/12 17:59
Prestige Consumer Healthcare (PBH) - Investor Presentation - Slideshow
The following slide deck was published by Prestige Consumer Healthcare Inc. in conjunction with this event.
Seekingalpha · 09/25 19:43
Are Investors Undervaluing Prestige Consumer Healthcare Inc. (NYSE:PBH) By 34%?
How far off is Prestige Consumer Healthcare Inc. (NYSE:PBH) from its intrinsic value? Using the most recent financial...
Simply Wall St. · 09/21 19:29
Prestige Brands (PBH) Down 9.7% Since Last Earnings Report: Can It Rebound?
Prestige Brands (PBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/05 15:31
Premium Brands Acquires Global Gourmet Foods and Signs and Agreement to Acquire Allseas Fisheries
The combined purchase price for the Company's investments in Global Gourmet and Allseas is approximately $139 million consisting of $115 million in cash, $10 million in Premium Brands
Benzinga · 08/31 11:14
Prestige Consumer Healthcare EPS beats by $0.16, beats on revenue
Prestige Consumer Healthcare (NYSE:PBH): Q1 GAAP EPS of $0.86 beats by $0.16. Revenue of $229.39M (-1.2% Y/Y) beats by $8.12M. Press Release
seekingalpha · 08/06 15:02
Prestige Brands (PBH) Q1 Earnings and Revenues Beat Estimates
Prestige Brands (PBH) delivered earnings and revenue surprises of 22.86% and 3.38%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/06 13:35
Prestige Consumer Healthcare Inc. Reports Fiscal 2021 First Quarter Results
* Revenue was $229.4 Million in First Quarter Fiscal 2021, Down 0.6% from Prior Year Q1 Excluding Unfavorable Foreign Currency * Diluted EPS of $0.86 in First Quarter Fiscal 2021, up 32% from Prior Year Q1 * Generated Cash from Operations of $75.2 Million an
GlobeNewswire · 08/06 10:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PBH. Analyze the recent business situations of Prestige Consumer through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PBH stock price target is 45.75 with a high estimate of 48.00 and a low estimate of 43.00.
EPS
Institutional Holdings
Institutions: 349
Institutional Holdings: 63.62M
% Owned: 126.77%
Shares Outstanding: 50.19M
TypeInstitutionsShares
Increased
89
3.73M
New
64
263.54K
Decreased
83
3.11M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.16%
Pharmaceuticals & Medical Research
+0.20%
Key Executives
Chairman/President/Chief Executive Officer/Director
Ronald Lombardi
Chief Financial Officer
Christine Sacco
Executive Vice President/Director of Sales/Director of Marketing
Adel Mekhail
Senior Vice President/General Counsel/Secretary
William PPool
Independent Director
John E. Byom
Senior Vice President
Jeffrey Zerillo
Lead Director/Independent Director
Gary Costley
Independent Director
John Byom
Independent Director
Christopher Coughlin
Independent Director
Sheila Hopkins
Independent Director
James Jenness
Independent Director
Natale Ricciardi
Independent Director
Dawn Zier
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 0.475
09/27/2018
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PBH
Prestige Consumer Healthcare Inc., formerly Prestige Brands Holdings, Inc. is engaged in the marketing, sales and distribution of over-the-counter healthcare products. The Company operates through two segments: North American Over-the-Counter (OTC) Healthcare, and International Over-the-Counter Healthcare. Its portfolio of OTC healthcare products includes core brands, such as DenTek specialty oral care products, Monistat women's health products, Nix lice treatment, Chloraseptic sore throat treatments, Clear Eyes eye care products, Compound W wart treatments, The Doctor's NightGuard dental protector, Little Remedies pediatric over-the-counter products, Efferdent denture care products, Luden's throat drops, Dramamine motion sickness treatment, BC and Goody's pain relievers, Beano gas prevention, Debrox earwax remover, and Gaviscon antacid.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Prestige Consumer Healthcare Inc stock information, including NYSE:PBH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PBH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PBH stock methods without spending real money on the virtual paper trading platform.